Japan's Takeda forecasts $1.76b operating loss on Shire acquisition

Shire logos sit on the boxes of Elvanse 50mg tablets, produced by Shire Plc, left, and Mezavant XL 1200mg tablets, produced by Shire Plc, in this arranged photograph taken at a pharmacy in London, U.K., on Tuesday, July 8, 2014. Photographer: Bloomberg/Bloomberg

Takeda Pharmaceutical Co forecast on Tuesday it would have an operating loss in the current financial year, as it books costs associated with the multibillion-dollar Shire deal.

Japan’s biggest drugmaker expects an operating loss of 193 billion yen ($1.76 billion) for the year to March 2020, compared with a 205 billion yen profit a year earlier.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter